Background
H. Lundbeck A/S markets Trintellix® (vortioxetine), an antidepressant approved by the FDA to treat major depressive disorder (MDD). Lundbeck held several patents related to vortioxetine, including two method-of-use patents that did not claim treatment of MDD but rather claimed other, narrower indications — such as treating cognitive dysfunction — as well as a manufacturing process patent. When generic manufacturers filed abbreviated new drug applications (ANDAs) seeking to market generic vortioxetine for treatment of MDD only, they carved out the patented non-MDD indications from their proposed drug labels. This “skinny label” strategy is a standard mechanism under the Hatch-Waxman Act allowing generics to enter the market with labels that omit patented uses.
Lundbeck sued the generic manufacturers, arguing that even with the label carve-outs, the generics would induce infringement of the method-of-use patents because physicians would foreseeably prescribe the generic drug for the omitted indications. The district court ruled for the generics, and Lundbeck appealed.
The Court’s Holding
The Federal Circuit unanimously affirmed. The court clarified the scope of Hatch-Waxman infringement under 35 U.S.C. § 271(e)(2)(A): a suit for infringement of a method-of-use patent is available only when the patent claims an indication for which the ANDA applicant is actually seeking marketing approval. Where a generic carves out a patented indication from its label and seeks approval only for a different, non-patented use, the method-of-use patent for the carved-out indication is simply not triggered under § 271(e)(2).
The court rejected Lundbeck’s inducement theory, holding that the relevant question is not whether physicians might prescribe the drug off-label for a carved-out indication, but whether the ANDA itself sought approval for that indication. The statute’s text and structure confirm that Hatch-Waxman infringement is tied to the use for which approval is sought, not to all foreseeable downstream uses. The court also noted the policy concern: “A patentee may not use Hatch-Waxman to maintain its exclusivity merely by regularly filing a new patent application claiming a narrow method of use.” Allowing brands to block generics via patents on tangential indications would undermine the statute’s goal of promoting timely generic entry for unpatented uses.
Key Takeaways
- Under the Hatch-Waxman Act, a generic manufacturer that carves out a patented indication from its drug label and seeks approval only for a different, non-patented use does not infringe a method-of-use patent covering the carved-out indication — even if physicians may foreseeably prescribe the drug off-label for that use.
- Hatch-Waxman § 271(e)(2) infringement for method-of-use patents is limited to the indication(s) for which the ANDA applicant actually seeks approval.
- Brand-name companies cannot extend drug exclusivity by filing patents on narrow, secondary indications and then asserting those patents against generics seeking approval only for the primary indication.
- The skinny label strategy remains a viable and legally protected mechanism for generic entry when genuine patented indications are carved out from the proposed label.
Why It Matters
This decision is a significant win for generic drug manufacturers and, by extension, for patients who depend on affordable generic medications. The Federal Circuit’s ruling confirms that the skinny label mechanism works as designed: generics can enter the market for non-patented indications without facing infringement liability for omitted patented uses, even if off-label prescribing for those uses is likely. The decision curtails a strategy that brand-name pharmaceutical companies had used to expand the blocking power of method-of-use patents by arguing that any foreseeable downstream use triggers Hatch-Waxman liability.
For pharmaceutical companies managing life-cycle strategies, Lundbeck v. Lupin signals that filing new patents on narrow secondary indications is not a reliable mechanism to delay generic entry for the primary, FDA-approved use. Generics, for their part, should continue to carefully document the carve-out process and ensure their ANDA submissions do not seek approval for any patented indications.